Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares represent an interest in a China-based biopharmaceutical company specializing in antibody-based drug discovery and preclinical research services. The company focuses on developing therapies targeting oncology, autoimmune, inflammatory, metabolic and other diseases, using proprietary fully human antibody platforms such as its RenMice technology to generate monoclonal, bispecific and multispecific antibodies. Alongside its internal pipeline, which includes multiple clinical-stage antibody candidates, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. provides animal models, gene-editing, and preclinical pharmacology services to global pharmaceutical and biotechnology partners, creating a diversified revenue base across animal model sales, antibody development, and efficacy evaluation. Founded in 2009 and headquartered in Beijing, the company has expanded its operations to the United States and Europe, positioning itself as a global player in innovative biologic drug research and enabling partners worldwide to accelerate antibody discovery and development.